BioSpace News Archive

Siemens recently announced that it can provide a fully integrated modular production solution by leveraging its SIMATIC PCS 7 and SIMATIC Batch and Biostat STR DCU from Sartorius.

The Asia Pacific mHealth market is expected to observe impressive growth over the forecast period due to the increasing prevalence of chronic diseases, especially among geriatric population.

Since the introduction of medical imaging devices in the 20th century, the utilization of medical imaging technology has been gaining ground in Europe, aided by the enhanced healthcare policies and growing availability of high-quality medical equipment.

The growing frequency of renal diseases, alongside the noteworthy growth in geriatric population, has been a primary driver of the North America dialysis market forecast.

The burgeoning number of peripheral and coronary artery surgical procedures across the world is a key factor expected to accelerate the stents market over the forecast period.

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that on Friday, February 12, 2021, the company received Section 510(k) clearance from the Unites States Food and Drug Administration (FDA) of the company’s submission to expand the label of gammaCore nVNS to include the acute and preventive treatment of migraine in adolescents between 12 and 17 years of age. gammaCore is now cleared for most for

Highlights: RECCE ® 327, a synthetic anti-infective 99.9% efficacious in confirmatory in-vitro screening assay against SARS-CoV-2 virus SARS-CoV-2 virus no longer detectable by virus titration at 4,000 ppm – minimal toxicity to Vero cells

Tibidabo Scientific Industries Ltd (" Tibidabo Scientific "), a global leader and supplier of highly differentiated technology for scientific research, aerospace, and industrial markets, has today announced the appointment of John LaViola as its Chief Technology Officer (CTO) and Head of Business Development.

INOVIO (NASDAQ: INO) announced today that fourth quarter and year-end 2020 financial results will be released after the market close on March 1, 2021 .

Monte Rosa Therapeutics, a biotechnology company focused on discovering and developing precision medicines that degrade disease-causing proteins, announced today that leadership will participate in four upcoming virtual investor conferences, as follows: